David Burrowes – 2014 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by David Burrowes on 2014-06-11.
To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence (NICE) has recommended for (i) prostate cancer, (ii) lung cancer, (iii) bowel cancer, (iv) breast cancer and (v) kidney cancer through either single or multiple technology appraisals and under the end of life criteria in each year since NICE was established.
Norman Lamb
The consideration of end of life criteria was introduced into the National Institute for Health and Care Excellence’s (NICE) technology appraisal process in January 2009. NICE has advised that it has recommended the following treatments for prostate, lung, bowel and kidney cancer under its technology appraisal programme where the end of life criteria were applied. No treatments for breast cancer have been recommended under the end of life criteria.
|
Cancer |
Appraisal |
Technolo-gy appraisal |
|
Prostate |
abiraterone in combination with prednisone or prednisolone for the treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen |
TA259 |
|
Lung |
oral topotecan for small cell lung cancer |
TA184 |
|
pemetrexed (maintenance treatment) for non-small cell lung cancer |
TA190 |
|
|
Bowel |
sunitinib for gastrointestinal stromal tumours |
TA179 |
|
Kidney |
sunitinib (first-line) for renal cell carcinoma |
TA169 |
|
pazopanib for the first-line treatment of advanced renal cell carcinoma |
TA215 |
Source: National Institute for Health and Care Excellence
“
